June 26, 2020
SAN RAMON, Calif. — CooperVision has hired Justin Kwan, OD, FAAO, as Senior Manager, Myopia Management in its Professional & Academic Affairs group. In this newly created role, Dr. Kwan will be responsible for supporting the growth of the company’s myopia management business across North America. This includes its Brilliant Futures Myopia Management Program featuring MiSight 1 day, the first and only FDA-approved product1 clinically proven to slow the progression of myopia when initially prescribed for children 8-12 years old* in the United States.
Dr. Kwan will lead the roll-out and provide support of myopia management programs in partnership with eye care practitioners (ECPs) across the United States and Canada. He will work within CooperVision to help define and develop the myopia management strategy including key focus areas, major events, clinical papers, training plans, presentations, and marketing collateral, and ensure cross-functional alignment. In addition to helping develop strategic plans and initiatives, Dr. Kwan will also work to further deepen relationships with ECPs, schools and colleges of optometry, and other industry leaders involved in the field.
“This role requires someone who is extremely knowledgeable about myopia management and can apply that to support ECPs and wearers. We saw Justin’s passion shine through in his commitment to research and other professional engagements,” said Michele Andrews, OD, Senior Director of North America Professional & Academic Affairs at CooperVision. “Justin’s contributions will extend our Brilliant Futures Myopia Management Program, and in doing so advance the entire profession and change the lives of children and families for the better.”
Dr. Kwan has more than a decade of professional experience in both practice and educational settings. He comes to CooperVision from Professional Eye Care Center in Niles, Illinois, where he served as an optometrist since 2018. Prior to that, Dr. Kwan was on faculty at the Southern California College of Optometry (SCCO). He also completed a dry eye and contact lens research fellowship at SCCO after he graduated from the University of California, Berkeley in 2009. Dr. Kwan is Editor-in-Chief of Clinical and Refractive Optometry, chairs the American Academy of Optometry’s Fellows Doing Research SIG, and is the president of the Chicago North Side Optometric Society.
“Joining CooperVision at this stage is a once in a lifetime opportunity, at a time where the Brilliant Futures™ Myopia Management Program will help define how the profession addresses such a major public health issue. I’m looking forward to becoming part of ECPs’ teams as they grow their myopia management knowledge and practices,” said Dr. Kwan.
1 MiSight 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
* When compared to the children in the control group wearing a single vision 1-day contact lens over a 3-year period. Chamberlain P et al. A 3-year Randomized Clinical Trial of MiSight® Lenses for Myopia Control. Optom Vis Sci 2019; 96:556-567.